Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070

por Dong, S, Kang, S, Lonial, S, Khoury, HJ, Viallet, J, Chen, J
Publicado 2007

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

por Cortes, J.E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F.E., Apperley, J.F., Khoury, H.J., Talpaz, M., DiPersio, J., DeAngelo, D.J., Abruzzese, E., Rea, D., Baccarani, M., Müller, M.C., Gambacorti-Passerini, C., Wong, S., Lustgarten, S., Rivera, V.M., Clackson, T., Turner, C.D., Haluska, F.G., Guilhot, F., Deininger, M.W., Hochhaus, A., Hughes, T., Goldman, J.M., Shah, N.P., Kantarjian, H.
Publicado 2013